Table 1 Summary of patient characteristics, including sites of metastatic disease
| Â | Melanoma (%) N=314 | Renal cell carcinoma (%) N=186 |
|---|---|---|
Gender | Â | Â |
 Male | 187 (60) | 138 (74) |
 Female | 127 (40) | 48 (26) |
Age | Â | Â |
 Mean (SD) | 53.2 (11.9) | 57.3 (9.1) |
 Range | 20 -79 | 30 – 80 |
ECOG performance status | Â | Â |
 0 | 220 (71) | 136 (73) |
 1 | 85 (27) | 47 (25) |
 2 | 7 (2) | 3 (2) |
Sites of metastatic disease | Â | Â |
 Lymph node | 154 (49) | 39 (21) |
 Lung | 181 (58) | 137 (74) |
 Liver | 96 (31) | 31 (17) |
 Bone | 79 (25) | 43 (23) |
 Brain | 47 (15) | 14 (7) |
 Subcutaneous | 69 (22) | 1(1) |
Number of metastatic sites | Â | Â |
 1 | 42 (13) | 61 (33) |
 2 | 69 (22) | 50 (27) |
 3 | 54 (17) | 38 (20) |
 4 | 149 (48) | 37 (20) |
Prior treatment | Â | Â |
 Nephrectomy | 2 (1) | 162 (87) |
 Radiation | 139 (44) | 41 (22) |
 Chemotherapy | 28 (9) | 8 (4) |
 Immunotherapy | 119 (38) | 9 (5) |
 VEGF TKI | 0 (0) | 11 (6) |
 Other | 71 (23) | 24 (13) |